Post-marketing Surveillance for the Clinical Safety and Effectiveness of Eribulin Mesylate in Patients With Inoperable or Recurrent Breast Cancer
Phase of Trial: Phase IV
Latest Information Update: 05 Apr 2017
At a glance
- Drugs Eribulin (Primary)
- Indications Breast cancer
- Focus Therapeutic Use
- Sponsors Eisai Co Ltd
- 05 Apr 2017 Results of a mechanistic pharmacodynamic analysis (n=406), presented at the 108th Annual Meeting of the American Association for Cancer Research
- 20 Apr 2015 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov record.
- 18 Jan 2013 Primary endpoint amended as reported by ClinicalTrials.gov.